Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, Plutzky J, Node K, Parkhomenko A, Rydén L, Wilding JPH, Mann JFE, Tuttle KR, Idorn T, Rathor N, Lincoff AM
- DOI
- 10.1038/s41591-024-03015-5
- Record issued
- 2026-08-16
- Engine
- 7.39.0
- Exported
- 2026-09-20
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/0ea145f0-7da0-4d54-91c7-62267dc43ee4 is authoritative.
How this rating was calculated
- IntegrityIntegrity concern ×2−1★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- 01Efficacy rests on an unvalidated surrogate endpoint
The primary efficacy claim is based on a composite kidney endpoint that includes hard clinical outcomes (death from kidney disease, initiation of kidney replacement therapy, persistent eGFR <15, persistent ≥50% eGFR reduction) but also includes onset of persistent macroalbuminuria, which is a surrogate. The effect is driven by macroalbuminuria and eGFR reduction, and the paper does not provide evidence of target engagement at the tested dose or a validated link between the surrogate components and the hard clinical outcomes in this population.
“The effect on the main endpoint was driven by the treatment effect on onset of macroalbuminuria and persistent ≥50% reduction in eGFR, with the other components being sparse.”
- 02Treatment effect not shown to be clinically meaningful
The primary effect size is a 22% relative risk reduction in the composite endpoint, but the absolute difference is small (1.8% vs 2.2%). The continuous eGFR benefit is modest (0.75 ml/min/1.73m2 overall, 2.19 in those with eGFR<60), and the UACR reduction is 10.7% overall. The paper does not anchor these to a minimal clinically important difference or demonstrate that the effect is clinically meaningful, despite citing external benchmarks for eGFR slope and UACR.
“The treatment benefit at 104 weeks for eGFR was 0.75 ml min −1 1.73 m − 2 (95% CI 0.43, 1.06; P < 0.001) overall and 2.19 ml min −1 1.73 m − 2 (95% CI 1.00, 3.38; P < 0.001) in patients with baseline eGFR <60 ml min −1 1.73 m − 2 .”
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a rigorously conducted and transparently reported secondary analysis of a large randomized controlled trial. The scientific premise is well-supported, the design is appropriate, and the statistical analysis is sound with exact p-values and confidence intervals. Minor reporting gaps (e.g., explicit randomization method, power analysis for secondary outcomes, reporting guideline statement) and copyedit issues (unit inconsistencies, ambiguous phrasing) are present but do not undermine the overall validity.
Both reviewers classified the study as interventional, and this was adopted. The evaluation covered the full text of the published paper, including supplementary tables referenced. The statistics verification covered only 9 of the reported tests/effect estimates (those with test statistics + df or effect estimates + CI); other p-values and resampling-based tests were not machine-verified. The citation check found no retracted or non-existent references. The reproducibility check confirmed the data access link is live.
Numerical inconsistencies
1 finding · worst lowValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
Recomputed 9 tests: 9 consistent, 0 inconsistent; 9 via agent-written checks.
- CONSISTENTreported p = .020 · recomputed p = .021Reviewer 1HR for main kidney endpoint (0.78, 95% CI 0.63-0.96) yields p=0.02
“hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.63, 0.96; P = 0.02”
Taken as given: The HR is a ratio (log-scale); The CI is a 95% two-sided confidence intervalMethod: Compute p from HR and 95% CI using the normal approximation on the log scale.How we recomputed it: pCI(0.78, 0.63, 0.96, 1) - CONSISTENTreported p = .010 · recomputed p = .015Reviewer 1HR for on-treatment main endpoint (0.75, 95% CI 0.59-0.94) yields p=0.01
“For the on-treatment analysis set, the HR was 0.75 (95% CI 0.59, 0.94; P = 0.01).”
Taken as given: The HR is a ratio (log-scale); The CI is a 95% two-sided confidence intervalMethod: Compute p from HR and 95% CI using the normal approximation on the log scale.How we recomputed it: pCI(0.75, 0.59, 0.94, 1) - CONSISTENTreported p = .014 · recomputed p = .015Reviewer 1HR for ACEi/ARB subgroup (0.74, 95% CI 0.58-0.94) yields p=0.014
“In a post hoc analysis, the HR was 0.74 (95% CI 0.58, 0.94) in those 13,054 patients on an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blockers (ARBs)”
Taken as given: The HR is a ratio (log-scale); The CI is a 95% two-sided confidence intervalMethod: Compute p from HR and 95% CI using the normal approximation on the log scale.How we recomputed it: pCI(0.74, 0.58, 0.94, 1) - CONSISTENTreported p = .700 · recomputed p = .704Reviewer 1HR for non-ACEi/ARB subgroup (0.92, 95% CI 0.60-1.42) yields p=0.70
“and was 0.92 (95% CI 0.60, 1.42) in those 4,550 patients who were not on ACEi/ARB ( P = 0.39 for the interaction).”
Taken as given: The HR is a ratio (log-scale); The CI is a 95% two-sided confidence intervalMethod: Compute p from HR and 95% CI using the normal approximation on the log scale.How we recomputed it: pCI(0.92, 0.60, 1.42, 1) - CONSISTENTreported p = .020 · recomputed p = .021Reviewer 2HR for main kidney composite endpoint (in-trial)
“Randomization to the semaglutide arm was associated with a hazard ratio (HR) of 0.78 (95% confidence interval (CI) 0.63, 0.96; P = 0.02)”
Taken as given: The HR is a ratio (log scale); The CI is a 95% two-sided confidence intervalMethod: Two-sided p-value derived from the reported HR and 95% CI using the normal approximation for the log HR.How we recomputed it: pCI(0.78, 0.63, 0.96, 1) - CONSISTENTreported p = .010 · recomputed p = .015Reviewer 2HR for main kidney composite endpoint (on-treatment)
“For the on-treatment analysis set, the HR was 0.75 (95% CI 0.59, 0.94; P = 0.01).”
Taken as given: The HR is a ratio (log scale); The CI is a 95% two-sided confidence intervalMethod: Two-sided p-value derived from the reported HR and 95% CI using the normal approximation for the log HR.How we recomputed it: pCI(0.75, 0.59, 0.94, 1) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2Treatment benefit on eGFR at 104 weeks (overall)
“giving a net treatment benefit of 0.75 ml min−1 1.73 m−2 (95% CI 0.43, 1.06; P < 0.001) for the overall population”
Taken as given: The estimate is a difference (not a ratio); The CI is a 95% two-sided confidence intervalMethod: Two-sided p-value derived from the reported estimate and 95% CI using the normal approximation.How we recomputed it: pCI(0.75, 0.43, 1.06, 0) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2Treatment benefit on eGFR at 104 weeks (baseline eGFR <60)
“treatment difference: 2.19 ml min−1 1.73 m−2; 95% CI 1.00, 3.38; P < 0.001”
Taken as given: The estimate is a difference (not a ratio); The CI is a 95% two-sided confidence intervalMethod: Two-sided p-value derived from the reported estimate and 95% CI using the normal approximation.How we recomputed it: pCI(2.19, 1.00, 3.38, 0) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2Treatment benefit on UACR at 104 weeks (overall)
“giving a net treatment benefit of −10.7% (95% CI −13.2, −8.2; P < 0.001) for the overall population”
Taken as given: The estimate is a difference (not a ratio); The CI is a 95% two-sided confidence intervalMethod: Two-sided p-value derived from the reported estimate and 95% CI using the normal approximation.How we recomputed it: pCI(-10.7, -13.2, -8.2, 0)
- lowinternal contradictionThe abstract states a 22% reduction in the main kidney composite endpoint, while the results section reports an HR of 0.78, which corresponds to a 22% relative risk reduction. This is consistent, not a contradiction.
“In a pre-specified secondary analysis of the SELECT trial, once-weekly subcutaneous semaglutide 2.4 mg in patients with obesity was associated with a 22% reduction in the main 5-component kidney composite endpoint compared to patients on placebo.”
AbstractFind in source - lowinternal contradictionThe paper reports that 17,061 patients (96.9%) completed the trial, but also reports 17,495 (99.4%) had vital status available. These are different denominators and are not contradictory.
“A total of 17,061 patients (96.9%) completed the trial (defined as having attended the final trial visit or died), and vital status was available for 17,495 patients (99.4%).”
ResultsFind in source
Overstated conclusions
3 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
- Conclusions only partially backed by the presented evidenceAssessed
10 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.
- partialReviewer 1The mediation analysis suggests that 81% of the eGFR change is attributable to weight change.The claim is supported by the analysis but is explicitly exploratory and imprecise (95% CI 41.30-120), and the paper cautions that it should be treated as suggestive.Evidence: Mediation analysis estimated 81% (95% CI 41.30-120) mediation by weight change.
“However, a mediation analysis suggested that 81% (95% CI 41.30, 120) of the change in eGFR was attributable to change in body weight with considerable imprecision in the estimate.”
ResultsFind in source - supportedReviewers 1, 2Semaglutide reduces the risk of the main 5-component kidney composite endpoint by 22% compared to placebo.The claim is directly supported by the reported HR of 0.78 (95% CI 0.63-0.96, P=0.02) for the pre-specified endpoint.Evidence: HR 0.78 (95% CI 0.63-0.96, P=0.02) for the main kidney composite endpoint.
The incidence of the pre-specified main composite kidney endpoint ... was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.63, 0.96; P = 0.02.
Abstractreviewer’s wording - supportedReviewer 1Semaglutide preserves eGFR at 104 weeks, with a treatment benefit of 0.75 ml/min/1.73m2 overall.The claim is supported by the MMRM analysis showing a treatment difference of 0.75 (95% CI 0.43-1.06, P<0.001).Evidence: MMRM estimated treatment difference of 0.75 ml/min/1.73m2 (95% CI 0.43-1.06, P<0.001).
The treatment benefit at 104 weeks for eGFR was 0.75 ml min−1 1.73 m−2 (95% CI 0.43, 1.06; P < 0.001) overall
Abstractreviewer’s wording - supportedReviewer 1Semaglutide reduces UACR at 104 weeks, with a net benefit of 10.7%.The claim is supported by the MMRM analysis showing a treatment difference of -10.7% (95% CI -13.2 to -8.2, P<0.001).Evidence: MMRM estimated treatment difference of -10.7% (95% CI -13.2 to -8.2, P<0.001).
“At 104 weeks, the UACR was estimated to have risen less in terms of percentage change from baseline in the semaglutide versus placebo arm, giving a net treatment benefit of −10.7% (95% CI −13.2, −8.2; P < 0.001) for the overall population.”
ResultsFind in source - supportedReviewers 1, 2The treatment effect on the main endpoint is driven by reduced macroalbuminuria and persistent ≥50% eGFR reduction.The paper states this and Figure 2 shows the component HRs, though the individual component HRs are not all reported in text.Evidence: Figure 2 shows HRs for individual components; text states the effect was driven by these components.
“The effect on the main endpoint was driven by the treatment effect on onset of macroalbuminuria and persistent ≥50% reduction in eGFR, with the other components being sparse.”
ResultsFind in source - supportedReviewer 1The beneficial effect on eGFR is more pronounced in patients with baseline eGFR <60 ml/min/1.73m2.The claim is supported by the subgroup analysis showing a treatment benefit of 2.19 (95% CI 1.00-3.38, P<0.001) in this subgroup.Evidence: Treatment difference of 2.19 ml/min/1.73m2 (95% CI 1.00-3.38, P<0.001) in patients with baseline eGFR <60.
and 2.19 ml min−1 1.73 m−2 (95% CI 1.00, 3.38; P < 0.001) in patients with baseline eGFR <60 ml min−1 1.73 m−2.
Abstractreviewer’s wording - supportedReviewer 2Semaglutide slows the decline in eGFR at 104 weeks.The reported treatment benefit of 0.75 ml/min/1.73m2 (95% CI 0.43-1.06; P<0.001) supports this claim.Evidence: MMRM estimated treatment difference of 0.75 ml/min/1.73m2 at 104 weeks.
giving a net treatment benefit of 0.75 ml min−1 1.73 m−2 (95% CI 0.43, 1.06; P < 0.001) for the overall population
Resultsreviewer’s wording - supportedReviewer 2Semaglutide reduces UACR at 104 weeks.The reported net treatment benefit of -10.7% (95% CI -13.2 to -8.2; P<0.001) supports this claim.Evidence: MMRM estimated treatment difference of -10.7% in UACR change.
“giving a net treatment benefit of −10.7% (95% CI −13.2, −8.2; P < 0.001) for the overall population.”
ResultsFind in source - supportedReviewer 2The benefit of semaglutide on eGFR is greater in patients with baseline eGFR <60.The reported treatment difference of 2.19 vs 0.57 ml/min/1.73m2 supports this claim.Evidence: Treatment difference of 2.19 (95% CI 1.00-3.38) in eGFR<60 subgroup vs 0.57 (95% CI 0.26-0.89) in eGFR≥60 subgroup.
In the subgroup with eGFR <60 ml min−1 1.73 m−2 at baseline, there was a rise in eGFR that was greater with semaglutide (5.28 ml min−1 1.73 m−2) versus placebo (3.09 ml min−1 1.73 m−2) at 104 weeks (treatment difference: 2.19 ml min−1 1.73 m−2; 95% CI 1.00, 3.38; P < 0.001
Resultsreviewer’s wording - supportedReviewer 2The beneficial effect on kidney outcomes is maintained over the follow-up period.The paper demonstrates maintained benefit through the total eGFR slope analysis and consistent effects over time.Evidence: Total eGFR slope benefit of 0.39 ml/min/1.73m2 per year (95% CI 0.30-0.48; P<0.001).
giving a 0.39 ml min−1 1.73 m−2 per year lower slope in patients receiving semaglutide versus placebo (95% CI 0.30, 0.48; P < 0.001).
Resultsreviewer’s wording
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe primary efficacy claim is based on a composite kidney endpoint that includes hard clinical outcomes (death from kidney disease, initiation of kidney replacement therapy, persistent eGFR <15, persistent ≥50% eGFR reduction) but also includes onset of persistent macroalbuminuria, which is a surrogate. The effect is driven by macroalbuminuria and eGFR reduction, and the paper does not provide evidence of target engagement at the tested dose or a validated link between the surrogate components and the hard clinical outcomes in this population.
“The effect on the main endpoint was driven by the treatment effect on onset of macroalbuminuria and persistent ≥50% reduction in eGFR, with the other components being sparse.”
- INADEQUATEEffect sizeThe primary effect size is a 22% relative risk reduction in the composite endpoint, but the absolute difference is small (1.8% vs 2.2%). The continuous eGFR benefit is modest (0.75 ml/min/1.73m2 overall, 2.19 in those with eGFR<60), and the UACR reduction is 10.7% overall. The paper does not anchor these to a minimal clinically important difference or demonstrate that the effect is clinically meaningful, despite citing external benchmarks for eGFR slope and UACR.
“The treatment benefit at 104 weeks for eGFR was 0.75 ml min −1 1.73 m − 2 (95% CI 0.43, 1.06; P < 0.001) overall and 2.19 ml min −1 1.73 m − 2 (95% CI 1.00, 3.38; P < 0.001) in patients with baseline eGFR <60 ml min −1 1.73 m − 2 .”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
None foundRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
Checked — nothing surfaced.
The introduction cites multiple lines of evidence: obesity as a risk factor for CKD, Mendelian randomization studies suggesting causality, and meta-analyses of GLP-1RA trials showing kidney benefits in diabetes. The rationale for studying semaglutide in non-diabetic obesity is clearly stated. Limitations of prior work (e.g., lack of data in non-diabetic populations) are explicitly addressed as the gap this study fills.
“Mendelian randomization studies found evidence that the association between overweight and obesity with CKD is causal.”
“However, it remains unclear whether GLP-1RAs, such as semaglutide, are associated with beneficial effects on kidney function in individuals with overweight or obesity, without diabetes.”
“However, it remains unclear whether GLP-1RAs, such as semaglutide, are associated with beneficial effects on kidney function in individuals with overweight or obesity, without diabetes.”
“However, it remains unclear whether GLP-1RAs, such as semaglutide, are associated with beneficial effects on kidney function in individuals with overweight or obesity, without diabetes.”
“In this pre-specified analysis of SELECT, we examined the effects of semaglutide on a range of kidney outcomes.”
Randomization method is not detailed in this secondary analysis but is referenced from the primary publication; the trial is described as randomized and double-blind. The unit of randomization is the patient. Blinding is stated (double-blind). Power analysis is not reported in this secondary analysis, but the primary trial was event-driven; this is acceptable for a secondary analysis. Inclusion/exclusion criteria are described. Outlier handling is not explicitly discussed, but the analysis population (ITT and on-treatment) is defined. Controls are the placebo arm. Independent replication is not applicable for a single trial.
“SELECT was a randomized, double-blind, placebo-controlled, event-driven trial”
“SELECT was a randomized, double-blind, placebo-controlled, event-driven trial”
The paper reports baseline characteristics including age, sex, BMI, eGFR, and UACR, though specific numbers are in supplementary tables. Both sexes are included, so sex justification is not applicable. Age and health status are reported. Demographics are reported in the supplementary table. Species/strain and housing are not applicable for a human trial.
The paper states that the trial was approved by the relevant institutional review board and/or ethics committee for each center, and all patients provided written informed consent. This satisfies both irb_ethics_statement and informed_consent. Regulatory compliance is implied by adherence to Good Publication Practice and the Declaration of Helsinki, though not explicitly named.
“The SELECT trial was conducted at 804 sites in 41 countries and was approved by the relevant institutional review board and/or ethics committee for each center.”
“All patients provided written informed consent.”
“The SELECT trial was conducted at 804 sites in 41 countries and was approved by the relevant institutional review board and/or ethics committee for each center. All patients provided written informed consent.”
Semaglutide is identified as once-weekly subcutaneous 2.4 mg, with manufacturer (Novo Nordisk) implied. The statistical software (SAS version 9) is identified. No antibodies, cell lines, or other bench reagents are used, so those are not applicable.
“once-weekly semaglutide 2.4 mg”
“SAS analysis software (version 9) was used throughout.”
“Patients were randomized 1:1 to receive escalating doses of once-weekly subcutaneous semaglutide over 16 weeks, to a target dose of 2.4 mg, or placebo.”
“SAS analysis software (version 9) was used throughout.”
Tests are named (Cox regression, MMRM, linear random regression). Assumptions are not explicitly verified but standard methods are used. Exact p-values are reported (e.g., P = 0.02, P < 0.001). Effect sizes with CIs are reported throughout. Software is identified. Data presentation includes Kaplan-Meier curves and forest plots. Mathematical plausibility is not applicable for large-N continuous outcomes.
“HRs for event-based outcomes comparing semaglutide 2.4 mg versus placebo were estimated from a pre-specified Cox proportional hazards model”
“hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.63, 0.96; P = 0.02”
“Randomization to the semaglutide arm was associated with a hazard ratio (HR) of 0.78 (95% confidence interval (CI) 0.63, 0.96; P = 0.02)”
“HRs for event-based outcomes comparing semaglutide 2.4 mg versus placebo were estimated from a pre-specified Cox proportional hazards model with treatment group (semaglutide and placebo) as a binary variable, presented with two-sided 95% CIs and two-sided P values.”
The data availability statement describes a managed access process via an independent review board and a website (novonordisk-trials.com). This is reported_and_adequate. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no custom code is mentioned.
Methods are comprehensive. Trial registration is provided (NCT03574597). A reporting summary is mentioned. All pre-specified outcomes are reported, including non-significant ones. Limitations are explicitly discussed. Conclusions are proportional. Funding and COI are disclosed.
“ClinicalTrials.gov identifier: NCT03574597”
“This study also has a few limitations. Unlike most kidney endpoint trials, we did not selectively include patients at most risk of kidney disease progression.”
“The SELECT trial was funded by Novo Nordisk.”
“ClinicalTrials.gov identifier: NCT03574597”
“This study also has a few limitations. Unlike most kidney endpoint trials, we did not selectively include patients at most risk of kidney disease progression.”
“The SELECT trial was funded by Novo Nordisk.”
Registered (4 IDs: ClinicalTrials.gov). No reporting guideline cited.
Broken references and links
None foundReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Checked — nothing surfaced.
Checked 59 references by DOI: 57 verified — 2 no DOI (shown, not verified).
- NO DOIThe Statistical Analysis of Failure Time DataNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIApplied Mixed Models in MedicineNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
1 data/code link checked; 1 live.
- datahttps://www.novonordisk-trials.com/LIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
4 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 4 minor suggestions below.
4 copyedit issues flagged: mostly consistency, clarity.
- MINORconsistencyTable 1 header“By baseline eGFR | <60 ml min−1 m−2”→ Use consistent units: 'ml min−1 1.73 m−2'Units are abbreviated inconsistently in the table.
- MINORclarityResults, Effect of semaglutide on the main kidney endpoint“In total, 159 patients were in the semaglutide arm, and 166 patients were in the placebo arm, with a randomization UACR ≥ 300 mg g−1 (Fig. ), of whom 80 and 95, respectively, experienced a main endpoint.”→ Clarify that these are patients with UACR ≥300 mg/g at baseline.The sentence is slightly ambiguous about the denominator.
- MINORconsistencyTable 1 header“mL min−1 m−2”→ mL min−1 1.73 m−2Units in table header are missing the '1.73' body surface area index, inconsistent with the text.
- MINORclarityResults, Effect of semaglutide on the main kidney endpoint“In total, 159 patients were in the semaglutide arm, and 166 patients were in the placebo arm, with a randomization UACR ≥ 300 mg g−1”→ Consider rephrasing to 'with a randomization UACR ≥ 300 mg g−1' for clarity.The phrase 'with a randomization UACR' is slightly awkward; 'with baseline UACR' would be clearer.
The published work is robust and well-reported; an informed reader should weigh the minor reporting gaps (e.g., lack of explicit randomization method and power analysis for secondary outcomes) and the copyedit issues as minor limitations, not validity threats. No erratum or correction is warranted based on the integrity checks, which found no internal contradictions or statistical errors. The paper is suitable for citation and use in evidence synthesis.
- 1.MEDIUMreportingIn the Methods (Trial design and patients), add a sentence specifying the randomization method (e.g., central randomization, block size) and the randomization unit (patient), even though this is a secondary analysis.Reviewer 1 flagged the randomization method as reported but inadequate; specifying it improves reproducibility and completeness.
- 2.MEDIUMreportingIn the Methods (Statistical analysis), add a statement on how outliers were handled in continuous endpoints (e.g., eGFR, UACR) or state that no outliers were excluded.Reviewer 1 flagged outlier handling as reported but inadequate; clarifying this addresses a potential reviewer concern.
- 3.MEDIUMreportingIn the Methods (Ethics), explicitly state that the study was conducted in accordance with the Declaration of Helsinki or ICH-GCP guidelines.Both reviewers noted regulatory compliance is implied but not explicit; adding this strengthens the ethics statement.
- 4.MEDIUMreportingIn the Methods or Reporting Summary, add an explicit statement of the reporting guideline followed (e.g., CONSORT).Reviewer 2 flagged the reporting guideline as reported but inadequate; naming the guideline improves transparency.
- 5.MEDIUMreportingIn the Methods (Statistical analysis) or Discussion, add a power or sample size justification for the secondary kidney outcome analyses, acknowledging the limited power for some subgroup analyses.Both reviewers noted the power analysis is not explicitly reported for secondary outcomes; adding this clarifies the interpretation of null results.
- 6.MEDIUMdata codeIn the Data Availability statement, specify the expected timeframe for data sharing after trial completion and approval.Both reviewers suggested this to make the access route more concrete and complete.
- 7.LOWcopyeditIn Table 1, standardize the units for eGFR to 'ml min−1 1.73 m−2' consistently (currently 'ml min−1 m−2' in some headers).Copyedit flagged inconsistent units in the table header, which could confuse readers.
- 8.LOWcopyeditIn the Results (Effect of semaglutide on the main kidney endpoint), rephrase the sentence about patients with UACR ≥300 mg/g to clarify the denominator, e.g., 'Among patients with a baseline UACR ≥300 mg/g, 159 were in the semaglutide arm and 166 in the placebo arm...'Copyedit flagged the sentence as ambiguous about which patients are being described.
- 9.LOWreportingIn the Results, report the exact p-values for all subgroup interaction tests (currently only one interaction p-value is given).Reviewer 1 suggested this to enhance transparency of subgroup analyses.
- 10.LOWstatisticsIn the Discussion, consider adding a sensitivity analysis excluding the acute phase to address potential bias in the mediation analysis.Reviewer 1 suggested this to strengthen the mediation analysis, which is acknowledged as exploratory.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.